Mizuho Reiterates Buy on Terns Pharma, Maintains $16 Price Target
Portfolio Pulse from richadhand@benzinga.com
Mizuho analyst Graig Suvannavejh has reiterated a 'Buy' rating on Terns Pharma (NASDAQ:TERN) and maintained a price target of $16.
June 30, 2023 | 12:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mizuho has reiterated a 'Buy' rating on Terns Pharma and maintained a price target of $16.
The reiteration of a 'Buy' rating by Mizuho indicates a positive outlook for Terns Pharma. The maintained price target of $16 suggests that the analyst believes the stock has potential for growth. This could positively impact the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100